272 related articles for article (PubMed ID: 30343508)
1. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Clavé MM; Maeda NY; Thomaz AM; Bydlowski SP; Lopes AA
Congenit Heart Dis; 2019 Mar; 14(2):246-255. PubMed ID: 30343508
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
Sabri MR; Beheshtian E
Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
[TBL] [Abstract][Full Text] [Related]
3. Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension.
Maeda NY; Clavé MM; Bydlowski SP; Lopes AA
Thromb Res; 2016 Oct; 146():15-19. PubMed ID: 27564658
[TBL] [Abstract][Full Text] [Related]
4. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects.
Raja SG; Danton MD; MacArthur KJ; Pollock JC
J Cardiothorac Vasc Anesth; 2007 Apr; 21(2):203-7. PubMed ID: 17418732
[TBL] [Abstract][Full Text] [Related]
5. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
[TBL] [Abstract][Full Text] [Related]
6. Sildenafil Use in Children with Pulmonary Hypertension.
Cohen JL; Nees SN; Valencia GA; Rosenzweig EB; Krishnan US
J Pediatr; 2019 Feb; 205():29-34.e1. PubMed ID: 30396684
[TBL] [Abstract][Full Text] [Related]
7. Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Ried M; Neu R; Lehle K; Großer C; Szöke T; Lang G; Hofmann HS; Hoenicka M
Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):254-259. PubMed ID: 28486684
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
Sabri MR; Bigdelian H; Hosseinzadeh M; Ahmadi A; Ghaderian M; Shoja M
Cardiol Young; 2017 Nov; 27(9):1686-1693. PubMed ID: 28994364
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology.
Mori H; Park IS; Yamagishi H; Nakamura M; Ishikawa S; Takigiku K; Yasukochi S; Nakayama T; Saji T; Nakanishi T
Int J Cardiol; 2016 Oct; 221():122-7. PubMed ID: 27400308
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease.
Humpl T; Reyes JT; Erickson S; Armano R; Holtby H; Adatia I
Cardiol Young; 2011 Apr; 21(2):187-93. PubMed ID: 21138617
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.
Jaffey JA; Leach SB; Kong LR; Wiggen KE; Bender SB; Reinero CR
J Vet Cardiol; 2019 Aug; 24():7-19. PubMed ID: 31405557
[TBL] [Abstract][Full Text] [Related]
12. Acute vasodilator testing following Fontan palliation: an opportunity to guide precision care?
Day RW
Cardiol Young; 2020 Jun; 30(6):829-833. PubMed ID: 32441233
[TBL] [Abstract][Full Text] [Related]
13. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
Magee AG; Makhecha S; Bentley S
Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
[TBL] [Abstract][Full Text] [Related]
14. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension.
Ajami GH; Borzoee M; Radvar M; Amoozgar H
Pediatr Cardiol; 2008 May; 29(3):552-5. PubMed ID: 18058160
[TBL] [Abstract][Full Text] [Related]
16. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease.
Latus H; Wagner I; Ostermayer S; Kerst G; Kreuder J; Schranz D; Apitz C
Pediatr Cardiol; 2017 Oct; 38(7):1342-1349. PubMed ID: 28681131
[TBL] [Abstract][Full Text] [Related]
18. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum HMGB1 in pulmonary arterial hypertension secondary to congenital heart disease.
Huang YY; Su W; Zhu ZW; Tang L; Hu XQ; Zhou SH; Fang ZF; Li J
Vascul Pharmacol; 2016 Oct; 85():66-72. PubMed ID: 27568461
[TBL] [Abstract][Full Text] [Related]
20. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
